Evidence map›Paper›PMID 39238213›Full record

ArticleAlimentary pharmacology & therapeutics2024

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.

Daniela S Allende, Oscar Cummings, Alice L Sternberg, Cynthia A Behling, Danielle Carpenter, Ryan M Gill, Cynthia D Guy, Matthew M Yeh, Samer Gawrieh, Richard K Sterling and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Observational
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniela S AllendeCleveland Clinic, Cleveland, Ohio, USA.
Oscar CummingsDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Alice L SternbergJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Cynthia A BehlingPacific Rim Pathology, San Diego, California, USA.
Danielle CarpenterSaint Louis University, St. Louis, Missouri, USA.
Ryan M GillUniversity of California San Francisco, San Francisco, California, USA.
Cynthia D GuyDuke University, Durham, North Carolina, USA.
Matthew M YehUniversity of Washington, Seattle, Washington, USA.
Samer GawriehDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-2056-4909
Richard K SterlingVirginia Commonwealth University Health System, Richmond, Virginia, USA.
Susanna NaggieDuke Clinical Research Institute, Durham, North Carolina, USA.
Rohit LoombaUniversity of California San Diego, San Diego, California, USA.
Jennifer C PriceUniversity of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-3825-5696
Mary McLaughlinNational Institute of Allergy and Infectious Disease (NIAID), Bethesda, Maryland, USA.
Colleen HadiganNational Institute of Allergy and Infectious Disease (NIAID), Bethesda, Maryland, USA.
Holly CrandallDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Patricia BeltJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Laura WilsonJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Naga P ChalasaniDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-4082-3178
David E KleinerLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
HIV NASH and NASH Clinical Research Groups

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Continuation of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASHU01DK061730 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 2002 to 2018
$23.2M
San Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Intramural NIH HHS Z01 BC010685Intramural Research Program of the National Institutes of HealthNCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1TR000004NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1TR000006NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1TR000040NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1TR000077NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1TR000100NCATS NIH HHS UL1 TR000150NCATS NIH HHS UL1TR000150NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1TR000423NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1TR000424NCATS NIH HHS UL1 TR000436NCATS NIH HHS UL1TR000436NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1TR000448NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002649NCATS NIH HHS UL1TR002649NCATS NIH HHS UM1 TR004528NCI NIH HHSNIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01DK121378NIDDK NIH HHS U01 DK061713NIDDK NIH HHS U01DK061713NIDDK NIH HHS U01 DK061718NIDDK NIH HHS U01DK061718NIDDK NIH HHS U01 DK061728NIDDK NIH HHS U01DK061728NIDDK NIH HHS U01 DK061730NIDDK NIH HHS U01DK061730NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01DK061732NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01DK061734NIDDK NIH HHS U01 DK061737NIDDK NIH HHS U01DK061737NIDDK NIH HHS U01 DK061738NIDDK NIH HHS U01DK061738NIDDK NIH HHS U24 DK061730NIDDK NIH HHS U24DK061730
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is common in people with HIV (PWH). The morphological spectrum of MASLD compared to matched controls and of the correlation between the NAFLD activity score (NAS) and fibrosis stage in PWH remains unknown.

methodsOverall, 107 liver biopsies from PWH with MASLD (MASLD-PWH) were matched to 107 biopsies from individuals with MASLD and without HIV (MASLD controls) on age at biopsy, race/ethnicity, sex, type 2 diabetes, body mass index (BMI) and alanine aminotransferase (ALT) level. Biopsies were scored using NAS.

resultsCompared to MASLD-controls, MASLD-PWH had lower steatosis grade (OR: 0.65, 95% CI: (0.47-0.90), p = 0.01), lower lobular inflammation grade (OR: 0.55, 95% CI: (0.34-0.89), p = 0.02), less portal inflammation (OR: 0.42, 95% CI: (0.25-0.72), p = 0.002) and less ballooned hepatocytes (OR: 0.60, 95% CI: (0.41-0.88), p = 0.01). Thus, NAS was lower in MASLD-PWH (OR: 0.69, 95% CI: (0.56-0.85), p < 0.001) than in MASLD controls. There was a trend towards lower prevalence of steatohepatitis in MASLD-PWH (OR: 0.84, 95% CI: (0.68-1.03), p = 0.09). A multivariate analysis demonstrated that MASLD-PWH cases had significantly less steatosis (OR: 0.66, p = 0.03), portal inflammation (OR: 0.34, p = 0.001) and ballooned hepatocytes (OR: 0.55, p = 0.01), yet higher stage fibrosis (OR: 1.42, p = 0.03) compared to MASLD controls.

conclusionThe NAS and histological drivers of fibrosis (e.g. inflammation and hepatocyte ballooning) are less pronounced in MASLD-PWH, and yet fibrosis stage was generally higher when compared to matched controls with MASLD without HIV. This suggests HIV-specific factors beyond hepatic necroinflammation may contribute to fibrosis progression in MASLD-PWH.

Indexed as

HIV InfectionsLiver CirrhosisAdultBiopsyBody Mass IndexCase-Control StudiesFatty LiverFemaleHumansLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseSeverity of Illness Index

Identifiers

PMID39238213
PMCPMC11499004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.